Akari Therapeutics Plc Stock Price, News & Analysis

Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has announced its participation in the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. President and CEO Abizer Gaslightwala will present and discuss recent corporate developments on Thursday, May 29, 2025, at 2:20 PM ET. The presentation will be accessible through a webcast, with registration available for interested participants.

Akari Therapeutics (NASDAQ: AKTX) reported Q1 2025 financial results and provided updates on its ADC development program. The company is developing novel Antibody Drug Conjugates with immuno-oncology payloads for cancer treatment, with its lead asset AKTX-101 targeting Trop2. The company appointed Mark Kubik as Head of Business Development - Oncology.

Financial highlights include a reduced net loss of $3.7 million compared to $5.6 million in Q1 2024. R&D expenses decreased to $0.8 million from $2.3 million, while G&A expenses dropped to $2.7 million from $3.7 million. The company held $2.6 million in cash as of March 31, 2025, with an additional $4.0 million received in April from a March 2025 offering that raised $6.0 million net.

Key upcoming milestones include presenting preclinical data for their PH1 payload ADC in H2 2025, exploring AKTX-101 in various solid tumors, and seeking strategic partnerships.

Akari Therapeutics (NASDAQ: AKTX) has appointed Mark F. Kubik as Head of Business Development - Oncology. Kubik brings over 25 years of experience in transformative deal creation and productive alliances, particularly in ADCs and antibody therapies. His notable achievements include leading transactions at companies like SeaGen (now Pfizer), Abgenix (now Amgen), and OncoImmune, where he orchestrated a $425M sale to Merck. Most recently, he served as Senior VP of U.S and EU Business Development at I-MAB Biopharma. At Akari, Kubik will focus on business development for the company's novel ADC platform and lead asset AKTX-101, a potential first-in-class immuno-oncology ADC therapy targeting Trop2 for multiple solid tumors.

Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has released a corporate update video featuring their newly appointed President and Chief Executive Officer, Abizer Gaslightwala. The video, released on April 22, 2025, is available on the company's website under the Investors section's Presentations page at www.akaritx.com.

Akari Therapeutics (NASDAQ: AKTX) reported its 2024 financial results and corporate updates, marking a transformational year following its merger with Peak Bio Inc. The company is advancing next-generation precision bi-functional Antibody Drug Conjugates (ADCs) for cancer treatment.

Their lead program, AKTX-101, targets solid tumors with a novel spliceosome inhibitor payload, showing superior activity and better tolerability in preclinical models. The company reported a net loss of $21.6 million for 2024, compared to $16.8 million in 2023, with research and development expenses of $7.0 million.

With approximately $2.6 million cash as of December 2024, plus $6.6 million from a March 2025 private placement, Akari expects to fund operations into September 2025. The company appointed Abizer Gaslightwala as new CEO effective April 21, 2025, and is seeking licensing/strategic partners for AKTX-101.

Akari Therapeutics (NASDAQ: AKTX) has appointed Abizer Gaslightwala as President and CEO, effective April 21, 2025. Gaslightwala brings 25 years of biotechnology and pharmaceutical industry experience, most recently serving as SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, where he managed a $1B product portfolio.

The current President and CEO, Dr. Samir Patel, will remain on the Company's Board of Directors. During his 12-month tenure, Dr. Patel oversaw the successful merger of Peak Bio with Akari, transforming it into a targeted oncology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADCs) for cancer treatment.

Gaslightwala's extensive experience includes executive leadership roles at Amgen, Pfizer, and Johnson & Johnson, where he worked with major brands such as Kyprolis®, Vectibix®, and ELIQUIS®. He holds degrees from Cornell University and MIT, including an MBA from MIT Sloan School of Management.

Akari Therapeutics (Nasdaq: AKTX) has announced a private placement offering expected to raise $7.6 million in gross proceeds, with strong support from existing shareholders and board members. The financing includes the issuance of 6,637,626 unregistered American Depository Shares (ADSs) priced at $0.87 per ADS, along with Series A and B Warrants.

The deal structure includes the conversion of an existing $1 million convertible note by Board Chairman Dr. Huh, with expected cash proceeds of $6.6 million before fees. The warrants will have an exercise price of $0.87 per ADS, with Series A and B having terms of one and five years respectively.

Funds will be allocated towards the company's spliceosome inhibitor payload ADC technology platform, seeking license partners for its TROP-2 ADC program, and monetizing non-core assets. Paulson Investment Company serves as placement agent, with closing expected around March 5, 2025.

Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference.

During the event, CEO Dr. Samir Patel presented the top five reasons why investors and industry colleagues should focus on Akari in 2025. The presentation is now available for viewing online through the company's website and the conference platform.

Akari Therapeutics (NASDAQ: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has announced its participation in the Webull Corporate Connect Service (CCS) platform. This initiative aims to enhance shareholder communication and transparency by providing an additional channel for distributing corporate updates, including company news, earnings reports, product developments, and presentations.

Through the Webull CCS platform, AKTX will maintain direct communication with investors and release timely notifications about corporate developments. The company views this as a strategic addition to their existing corporate social channels and investor relations program, designed to build market awareness and increase visibility among investors.